MELSMON
2 mL x 50 ampules
Description
MELSMON is a Japanese-approved human placenta hydrolysate injectable (Melsmon Pharmaceutical Co., approved 1956) containing amino acids, peptides, growth factors, vitamins, enzymes, and benzyl alcohol as a preservative-analgesic. Subcutaneous or intramuscular administration stimulates cellular regeneration, improves skin elasticity, and is the only product in this range with official Ministry of Health, Labour and Welfare approval specifically for menopausal disorder management. The low-molecular-weight bioactive fraction supports hepatic function, fatigue reduction, and dermal rejuvenation concurrently.
Indication
Designed for use within placental therapy protocols administered by qualified medical professionals operating under appropriate clinical supervision and treatment frameworks.
Packaging
Each box contains 50 ampoules of 2mL MELSMON placenta injection.
Protocol
Administer 1–2 ampoules (2–4 mL) via subcutaneous or IM injection 2–3 times per week for the first 2–4 weeks, then taper to once or twice weekly for 2–3 months. For menopausal indications, begin with 1 ampoule every other day for 2–3 weeks. Intravenous administration is contraindicated. Aesthetic mesotherapy protocols may target intradermal papular injection at 1–2 cm grid spacing across the face or décolletage.
